Izotropic's "Izotropic Africa" Enters Partnership Discussions with the Mohammed VI Foundation for Science & Health

Rhea-AI Summary

Izotropic (OTCQB:IZOZF) said its Casablanca-based venture Izotropic Africa has entered partnership discussions with the Mohammed VI Foundation for Science & Health to pursue clinical research, regulatory approval, and localized manufacturing for the IzoView Breast CT Imaging System.

Under a Letter Agreement Izotropic would hold a 40% fully diluted interest in Izotropic Africa, and the parties aim to finalize a Formal Agreement by April 30, 2026. Discussions include placing an IzoView device valued at USD $500K at a Moroccan hospital for clinical evaluation and exploring manufacturing and export advantages in Morocco.

Positive

• Planned 40% fully diluted ownership interest in Izotropic Africa
• Proposed placement of an IzoView device valued at USD $500K for clinical evaluation
• Target to finalize a Formal Agreement by April 30, 2026
• Access to Moroccan manufacturing incentives including VAT and tax exemptions

Negative

• Izotropic Africa ownership is subject to conditions and not finalized
• Current status limited to partnership discussions without binding commercial terms

Vancouver, British Columbia, and Sacramento, California--(Newsfile Corp. - February 25, 2026) - Izotropic Corporation (CSE: IZO) (OTCQB: IZOZF) (FSE: 1R3) ("Izotropic", or the "Company"), a medical device company commercializing innovative, emerging technologies and imaging-based products for the more accurate screening, diagnoses, and treatment of breast cancers, announces that, further to its February 18th announcement regarding the formation "Izotropic Africa" under a Letter Agreement, the proposed Casablanca-based entity has entered into partnership discussions with the Mohammed VI Foundation for Science & Health ("FM6SS"). The FM6SS operates as a public utility institution under the patronage of King Mohammed VI, supporting healthcare reform, research advancement, innovation, and institutional partnerships within Morocco.

Izotropic Africa is being developed to pursue the licensing, marketing, and distribution of the Company's proprietary IzoView Breast CT Imaging System and certain follow-on products throughout Africa and the Gulf Cooperation Council, which includes Bahrain, Kuwait, Oman, Qatar, Saudi Arabia, and the United Arab Emirates. Under the Letter Agreement, Izotropic will hold a 40% fully diluted interest in Izotropic Africa, subject to conditions, and the parties have agreed to negotiate in good faith to finalize and enter into a Formal Agreement by April 30, 2026.

The partnership discussions between Izotropic Africa and the FM6SS are focused on clinical research, regulatory advancement, and manufacturing and assembly opportunities in Morocco for the Company's proprietary medical device, the IzoView Breast CT Imaging System. As part of these discussions, an IzoView device valued at USD $500K would be placed at a leading hospital in Morocco at no cost as a clinical research site to support local clinical evaluation and regulatory approvals. The discussions also include the evaluation of opportunities for localized manufacturing and assembly initiatives in Morocco, with the kingdom's geographic position at the intersection of Europe, Africa, and the Middle East providing access to regional markets with established logistics channels.

As part of its broader manufacturing mission, the Kingdom of Morocco is advancing a coordinated national strategy to strengthen domestic medical device manufacturing, expand access to advanced healthcare technologies, and build long-term research and development capacity. In early February, during Morocco's second annual Medical Device Day, a 2026-2030 national framework agreement was signed by the Ministry of Health and Social Protection, the Ministry of Industry and Trade, the Moroccan Agency for Medicines and Health Products, the General Confederation of Moroccan Enterprises, and the Federation of the Medical Device Industry. The agreement outlines national priorities to strengthen domestic production capacity, reinforce supply-chain resilience, promote "Made in Morocco" manufacturing, support industrial investment, and align workforce development with sector growth.

Morocco operates 15 ports, including Tangier Med, the largest port in Africa and the Mediterranean, and offers more than 150 sector-specific industrial zones that enable companies to establish and scale production efficiently. Export-oriented industrial acceleration zones provide defined exemptions from value-added tax, business tax for 15 years, and corporate tax for five years.

The formalization of this national framework reinforces the strategic relevance of Izotropic Africa's discussions with FM6SS and supports the planned role of Izotropic Africa in advancing clinical research, regulatory progression, and localized manufacturing initiatives for IzoView Breast CT.

About Izotropic Africa:
Izotropic has entered into a Letter Agreement with a Business Group ("BG") to incorporate Izotropic Africa in Casablanca, Morocco, to establish operations, and pursue the licensing, marketing, and distribution of the Company's proprietary IzoView Breast CT Imaging System and certain follow-on products throughout Africa and the Gulf Cooperation Council (Bahrain, Kuwait, Oman, Qatar, Saudi Arabia, and the United Arab Emirates) while also evaluating manufacturing and/or assembly of in Morocco. BG will hold a 60% fully diluted interest in the entity, and Izotropic will hold a 40% fully diluted interest, subject to final corporate, tax, regulatory, repatriation structuring, and legal advice acceptable to both parties. The parties have agreed to negotiate in good faith to finalize and enter into a Formal Agreement by April 30, 2026.

About Izotropic:
More information about Izotropic Corporation can be found on its corporate website at izocorp.com and by reviewing its profile on SEDAR+ at sedarplus.ca.

Forward-Looking Statements:
This document may contain statements that are "Forward-Looking Statements," which are based upon the current estimates, assumptions, projections, and expectations of the Company's management, business, and its knowledge of the relevant market and economic environment in which it operates. The Company has tried, where possible, to identify such information and statements by using words such as "anticipate," "believe," "envision," "estimate," "expect," "intend," "may," "plan," "predict," "project," "target," "potential," "will," "would," "could," "should," "continue," "contemplate" and other similar expressions and derivations thereof in connection with any discussion of future events, trends or prospects or future operating or financial performance, although not all forward-looking statements contain these identifying words.

These statements are not guarantees of performance and involve risks, including those related to capital requirements and uncertainties that are difficult to control or predict, and as such, they may cause future results of the Company's activity to differ significantly from the content and implications of such statements. Forward-Looking Statements are pertinent only as of the date on which they are made, and the Company undertakes no obligation to update or revise any Forward-Looking Statements to reflect new information or the occurrence of future events or circumstances unless otherwise required to do so by law. Neither the Company nor its shareholders, officers, and consultants shall be liable for any action and the results of any action taken by any person based on the information contained herein, including, without limitation, the purchase or sale of Company securities. Nothing in this document should be deemed to be medical or other advice of any kind. All images are for illustrative purposes only. IzoView has not yet been approved or cleared for sale.

Contacts:
Robert Thast, Interim Chief Executive Officer
Telephone: 1-604-220-5031 or 1-833-IZOCORP ext. 1
Email: bthast@izocorp.com

General and Corporate Inquiries
Telephone: 1-604-825-4778 or 1-833-IZOCORP ext. 3
Email: info@izocorp.com

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/285211

FAQ

What does Izotropic (IZOZF) say about the proposed ownership of Izotropic Africa?

Izotropic would hold a 40% fully diluted interest in Izotropic Africa, subject to conditions. According to the company, the stake is defined under the Letter Agreement and depends on satisfying specified conditions before formalization.

What timeline did Izotropic (IZOZF) set to finalize the Izotropic Africa agreement?

The parties aim to finalize a Formal Agreement by April 30, 2026. According to the company, negotiations are ongoing and the date reflects the current target for completing definitive documentation.

Will Izotropic (IZOZF) place an IzoView device in Morocco for clinical research?

Yes; an IzoView device valued at USD $500K would be placed at a leading Moroccan hospital at no cost for local clinical evaluation. According to the company, this supports regulatory submissions and clinical data collection.

What manufacturing opportunities did Izotropic (IZOZF) discuss in Morocco?

Discussions include evaluating localized manufacturing and assembly initiatives to serve Africa and GCC markets. According to the company, Morocco's industrial zones and port access were cited as strategic advantages for exports.

Which markets will Izotropic Africa target under the proposed arrangement with Izotropic (IZOZF)?

Izotropic Africa is being developed to pursue licensing, marketing, and distribution across Africa and the GCC (Bahrain, Kuwait, Oman, Qatar, Saudi Arabia, UAE). According to the company, the entity will focus on regional market access and regulatory pathways.